阿立哌唑联合碳酸锂缓释片对双相情感障碍躁狂发作患者YMRS评分与生活质量的影响
|
摘要
目的:探究阿立哌唑口腔崩解片联合碳酸锂缓释片对双相情感障碍躁狂发作患者YMRS评分与生活质量的影响。方法:选取本院收治的双相情感障碍躁狂发作患者90例,按照随机数字表法分为对照组和研究组,各45例。对照组给予单纯碳酸锂缓释片治疗,研究组给予阿立哌唑口腔崩解片联合碳酸锂缓释片治疗。比较两组患者治疗前后YMRS评分、生活质量评分、临床疗效以及不良反应发生情况。结果:治疗2、6周后,两组患者YMRS评分均显著改善,且研究组的YMRS评分均低于对照组,差异均有统计学意义(P<0.05)。研究组患者临床总有效率为84.44%,显著高于对照组的57.78%,差异有统计学意义(P<0.05)。治疗6周后,研究组患者各维度评分和总分均显著升高,对照组患者心理功能、社会功能、躯体健康三个维度评分及总分均显著改善,且研究组患者在治疗6周后各维度评分及总分均显著高于对照组,差异均有统计学意义(P<0.05)。研究组患者不良反应发生率为37.78%,对照组为40.00%,两组比较差异无统计学意义(P>0.05)。结论:采用阿立哌唑口腔崩解片联合碳酸锂缓释片治疗双相情感障碍躁狂发作临床效果显著,安全性较好,值得推广使用。
Objective:To explore the effect of Aripiprazole Orally Disintegrating Tablets combined with Lithium Carbonate Sustained Release Tablets on YMRS score and quality of life in patients with bipolar disorder manic episode.Method:Ninety patients with bipolar disorder manic episode admitted to our hospital were selected,according to the random number table method,the patients were divided into control group and study group,45 cases in each group.The control group was treated with Lithium Carbonate Sustained Release Tablets alone,and the study group was treated with Aripiprazole Orally Disintegrating Tablets combined with Lithium Carbonate Sustained Release Tablets.YMRS score,quality of life score,clinical efficacy and adverse reactions before and after treatment were compared between the two groups.Result:After treatment for 2 and 6 weeks,YMRS scores in both groups were significantly improved,and YMRS scores in the study group were lower than those in the control group,with statistically significant differences(P<0.05).The total clinical effective rate of the study group was 84.44%,significantly higher than 57.78% of the control group,the difference was statistically significant(P<0.05).After 6 weeks of treatment,the scores of all dimensions and total scores in the study group were significantly increased,and the scores of psychological function,social function and physical health in the control group were significantly improved,and the scores of all dimensions and total scores in the study group were significantly higher than those in the control group after 6 weeks of treatment,with statistically significant differences(P<0.05).The incidence of adverse reactions was 37.78% in the study group and 40.00% in the control group,with no statistically significant difference between the two groups(P>0.05).Conclusion:Aripiprazole Oral Disintegrating Tablets combined with Lithium Carbonate Sustained Release Tablets in the treatment of bipolar disorder manic episode has significant clinical efficacy,good safety,and is worth popularizing.
Objective:To explore the effect of Aripiprazole Orally Disintegrating Tablets combined with Lithium Carbonate Sustained Release Tablets on YMRS score and quality of life in patients with bipolar disorder manic episode.Method:Ninety patients with bipolar disorder manic episode admitted to our hospital were selected,according to the random number table method,the patients were divided into control group and study group,45 cases in each group.The control group was treated with Lithium Carbonate Sustained Release Tablets alone,and the study group was treated with Aripiprazole Orally Disintegrating Tablets combined with Lithium Carbonate Sustained Release Tablets.YMRS score,quality of life score,clinical efficacy and adverse reactions before and after treatment were compared between the two groups.Result:After treatment for 2 and 6 weeks,YMRS scores in both groups were significantly improved,and YMRS scores in the study group were lower than those in the control group,with statistically significant differences(P<0.05).The total clinical effective rate of the study group was 84.44%,significantly higher than 57.78% of the control group,the difference was statistically significant(P<0.05).After 6 weeks of treatment,the scores of all dimensions and total scores in the study group were significantly increased,and the scores of psychological function,social function and physical health in the control group were significantly improved,and the scores of all dimensions and total scores in the study group were significantly higher than those in the control group after 6 weeks of treatment,with statistically significant differences(P<0.05).The incidence of adverse reactions was 37.78% in the study group and 40.00% in the control group,with no statistically significant difference between the two groups(P>0.05).Conclusion:Aripiprazole Oral Disintegrating Tablets combined with Lithium Carbonate Sustained Release Tablets in the treatment of bipolar disorder manic episode has significant clinical efficacy,good safety,and is worth popularizing.
引文
[1]张伟,盛磊,李金龙,等.阿立哌唑与碳酸锂对于双相情感障碍躁狂发作患者BRMS评分的影响[J].中国保健营养,2016,26(20):21-22.
[2]刘忠政,金莲玉.阿立哌唑联合丙戊酸钠与无抽搐电休克治疗双相情感障碍躁狂发作的疗效观察[J].社区医学杂志,2015,13(19):49-50.
[3]Sidhom Y,Ben D M,Hizem Y,et al.Bipolar Disorder and Multiple Sclerosis:A Case Series[J].Behavioural Neurology,2014,2014(2):536503.
[4]Tripathi P,Agrawal H,Goyal P,et al.Olanzapine-induced neuroleptic malignant syndrome in a patient with bipolar affective disorder:Does quetiapine holds the solution?[J].Industrial Psychiatry Journal,2014,22(2):159-160.
[5]史玉清,李长远,洪金时,等.丙戊酸镁缓释片联合碳酸锂缓释片治疗双相情感障碍躁狂发作期的临床疗效[J].临床合理用药杂志,2017,10(30):44-45.
[6]Passmore M J,Garnham J,Duffy A,et al.Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine[J].Bipolar Disorders,2015,5(2):110-114.
[7]张莹洁,迟勇,刘竞,等.双相情感障碍患者抑郁首发与躁狂首发的临床特点比较[J].中国医刊,2017,52(4):84-87.
[8]Sierra P,Livianos L,Rojo L.Quality of life for patients with bipolar disorder:relationship with clinical and demographic variables[J].Bipolar Disorders,2015,7(2):159-165.
[9]Carmaciu C D,Anderson C S,Lawton C A.Thyrotoxicosis after complete or partial lithium withdrawal in two patients with bipolar affective disorder[J].Bipolar Disorders,2015,5(5):381-384.
[10]陈少峰,刘义,李树珍.阿立哌唑联合丙戊酸钠缓释片治疗双相障碍躁狂发作的疗效及安全性观察[J].临床医学研究与实践,2017,2(10):50,68.
[11]Xiang Y T,Li L J,Zhou J J,et al.Quality of life of patients with euthymic bipolar disorder and its associations with demographic and clinical characteristics,psychopathology,and cognitive deficits[J].Perspectives in Psychiatric Care,2014,50(1):44-50.
[12]Maripuu M,Wikgren M,Karling P,et al.Relative Hypo and Hypercortisolism are Both Associated with Depression and Lower Quality of Life in Bipolar Disorder[J].Journal of Psychosomatic Research,2016,85(15):73-74.
[13]黄悦琦,洪武,邱美慧,等.中国双相情感障碍不同躁狂发作亚型危险因素的现况调查[J].中国心理卫生杂志,2015,29(12):927-932.
[14]胡希文,杨永秀,郭玉娟,等.重性抑郁障碍或双相障碍患者抑郁发作伴随躁狂症状的临床特征[J].临床精神医学杂志,2016,26(5):332-334.
[15]戴晓燕.G-CBT对双相情感障碍患者的治疗效果[J].西南国防医药,2018,28(3):242-244.
[16]郭辉,丁万涛.双相情感障碍患者情绪智力状况及其与疾病的关系[J].浙江医学,2017,39(12):999-1001.
[17]邢梦娟,洪武,黄佳,等.双相情感障碍躁狂相患者糖脂代谢相关因素分析[J].上海交通大学学报(医学版),2015,35(10):1474.
[18]吕贝,段海水,程伟,等.电休克治疗联合阿立哌唑、奥氮平治疗精神分裂症的效果评价[J].国际精神病学杂志,2017,44(2):34-37.
[19]Banerjee I,Sathian B,Chakraborty P K,et al.Pharmacotherapy of Bipolar Affective Disorder:A Hospital based Study from Sub Himalayan Valley of Nepal[J].Journal of Clinical&Diagnostic Research Jcdr,2014,8(6):HC22.
[20]Mohiuddin S.A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder[J].Applied Health Economics&Health Policy,2014,12(4):359-372.
[21]苏伟,钱敏才,沈鑫华,等.阿立哌唑对首发精神分裂症患者代谢影响的对照研究[J].浙江医学,2016,38(10):707-710.
[22]阿立哌唑治疗奥氮平所致精神分裂症患者体质量增加的随机双盲对照研究[J].临床精神医学杂志,2016,26(2):89-91.
[2]刘忠政,金莲玉.阿立哌唑联合丙戊酸钠与无抽搐电休克治疗双相情感障碍躁狂发作的疗效观察[J].社区医学杂志,2015,13(19):49-50.
[3]Sidhom Y,Ben D M,Hizem Y,et al.Bipolar Disorder and Multiple Sclerosis:A Case Series[J].Behavioural Neurology,2014,2014(2):536503.
[4]Tripathi P,Agrawal H,Goyal P,et al.Olanzapine-induced neuroleptic malignant syndrome in a patient with bipolar affective disorder:Does quetiapine holds the solution?[J].Industrial Psychiatry Journal,2014,22(2):159-160.
[5]史玉清,李长远,洪金时,等.丙戊酸镁缓释片联合碳酸锂缓释片治疗双相情感障碍躁狂发作期的临床疗效[J].临床合理用药杂志,2017,10(30):44-45.
[6]Passmore M J,Garnham J,Duffy A,et al.Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine[J].Bipolar Disorders,2015,5(2):110-114.
[7]张莹洁,迟勇,刘竞,等.双相情感障碍患者抑郁首发与躁狂首发的临床特点比较[J].中国医刊,2017,52(4):84-87.
[8]Sierra P,Livianos L,Rojo L.Quality of life for patients with bipolar disorder:relationship with clinical and demographic variables[J].Bipolar Disorders,2015,7(2):159-165.
[9]Carmaciu C D,Anderson C S,Lawton C A.Thyrotoxicosis after complete or partial lithium withdrawal in two patients with bipolar affective disorder[J].Bipolar Disorders,2015,5(5):381-384.
[10]陈少峰,刘义,李树珍.阿立哌唑联合丙戊酸钠缓释片治疗双相障碍躁狂发作的疗效及安全性观察[J].临床医学研究与实践,2017,2(10):50,68.
[11]Xiang Y T,Li L J,Zhou J J,et al.Quality of life of patients with euthymic bipolar disorder and its associations with demographic and clinical characteristics,psychopathology,and cognitive deficits[J].Perspectives in Psychiatric Care,2014,50(1):44-50.
[12]Maripuu M,Wikgren M,Karling P,et al.Relative Hypo and Hypercortisolism are Both Associated with Depression and Lower Quality of Life in Bipolar Disorder[J].Journal of Psychosomatic Research,2016,85(15):73-74.
[13]黄悦琦,洪武,邱美慧,等.中国双相情感障碍不同躁狂发作亚型危险因素的现况调查[J].中国心理卫生杂志,2015,29(12):927-932.
[14]胡希文,杨永秀,郭玉娟,等.重性抑郁障碍或双相障碍患者抑郁发作伴随躁狂症状的临床特征[J].临床精神医学杂志,2016,26(5):332-334.
[15]戴晓燕.G-CBT对双相情感障碍患者的治疗效果[J].西南国防医药,2018,28(3):242-244.
[16]郭辉,丁万涛.双相情感障碍患者情绪智力状况及其与疾病的关系[J].浙江医学,2017,39(12):999-1001.
[17]邢梦娟,洪武,黄佳,等.双相情感障碍躁狂相患者糖脂代谢相关因素分析[J].上海交通大学学报(医学版),2015,35(10):1474.
[18]吕贝,段海水,程伟,等.电休克治疗联合阿立哌唑、奥氮平治疗精神分裂症的效果评价[J].国际精神病学杂志,2017,44(2):34-37.
[19]Banerjee I,Sathian B,Chakraborty P K,et al.Pharmacotherapy of Bipolar Affective Disorder:A Hospital based Study from Sub Himalayan Valley of Nepal[J].Journal of Clinical&Diagnostic Research Jcdr,2014,8(6):HC22.
[20]Mohiuddin S.A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder[J].Applied Health Economics&Health Policy,2014,12(4):359-372.
[21]苏伟,钱敏才,沈鑫华,等.阿立哌唑对首发精神分裂症患者代谢影响的对照研究[J].浙江医学,2016,38(10):707-710.
[22]阿立哌唑治疗奥氮平所致精神分裂症患者体质量增加的随机双盲对照研究[J].临床精神医学杂志,2016,26(2):89-91.